Add like
Add dislike
Add to saved papers

Early experience with the Bard XT stent.

The Bard XT stent is a new generation balloon expandable intracoronary stent. It has several unique design advantages. Between October 1996 and November 1997, 127 Bard XT stents of various length were deployed in 93 patients with 109 lesions. According to the American College of Cardiology (ACC) and American Heart Association (AHA) classifications 7 lesions were type A, 38 were type B1, 43 were type B2 and 21 were type C [Ellis et al.: Circulation 82:1193-1202, 1990]. Stent delivery was successful in 98% of attempts. Angiographic success was achieved in 98% of 109 lesions. Procedural success was achieved in 94% of 93 patients. Minimal luminal diameter (MLD) increased from 0.91+/-0.34 mm to 3.03+/-0.44 mm and percentage diameter stenosis reduced from 69.1+/-11.07 to 9.96+/-6.81. Complications occurred in four patients. One patient had intracranial hemorrhage, one patient had subacute thrombosis and two patients died postprocedure. Patients were followed for a period of 1 to 14 months (average 7+/-4 months) for major cardiac events and clinical restenosis. The Bard XT stent is a user-friendly device which provided excellent angiographic results and short-term clinical outcome in selected cases. Further study is required to evaluate effects on restenosis.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app